The recent stock drop in Bicara Therapeutics Inc. is an overreaction, as the full phase 1/1b data—including key OS results—has yet to be released. BCAX interim data for FICERA plus KEYTRUDA in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback